Reviewing Bluejay Diagnostics (NASDAQ:BJDX) and AtriCure (NASDAQ:ATRC)

Bluejay Diagnostics (NASDAQ:BJDXGet Free Report) and AtriCure (NASDAQ:ATRCGet Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.


This table compares Bluejay Diagnostics and AtriCure’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bluejay Diagnostics N/A -110.89% -91.31%
AtriCure -6.52% -6.37% -4.95%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Bluejay Diagnostics and AtriCure, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bluejay Diagnostics 0 1 0 0 2.00
AtriCure 0 0 7 0 3.00

AtriCure has a consensus target price of $60.13, suggesting a potential upside of 71.44%. Given AtriCure’s stronger consensus rating and higher possible upside, analysts clearly believe AtriCure is more favorable than Bluejay Diagnostics.

Institutional and Insider Ownership

17.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 94.3% of AtriCure shares are held by institutional investors. 47.0% of Bluejay Diagnostics shares are held by company insiders. Comparatively, 3.0% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Bluejay Diagnostics has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500.

Earnings and Valuation

This table compares Bluejay Diagnostics and AtriCure’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bluejay Diagnostics $250,000.00 13.59 -$9.30 million ($9.63) -0.35
AtriCure $380.73 million 4.37 -$46.47 million ($0.54) -64.94

Bluejay Diagnostics has higher earnings, but lower revenue than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.


AtriCure beats Bluejay Diagnostics on 9 of the 14 factors compared between the two stocks.

About Bluejay Diagnostics

(Get Free Report)

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

About AtriCure

(Get Free Report)

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with's FREE daily email newsletter.